LINC6: Non-interventional Study on Osilodrostat in Patients With Endogenous Cushing's Syndrome
Study Details
Study Description
Brief Summary
This is a non-interventional, multinational, multi-centre study with primary data collection, to further document the safety and efficacy of osilodrostat administered in routine clinical practice in patients treated with osilodrostat for endogenous Cushing's Syndrome
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
Detailed Description
This is a non-interventional, multinational, multi-centre study with primary data collection, to further document the safety and efficacy of osilodrostat administered in routine clinical practice in patients treated with osilodrostat for endogenous Cushing's Syndrome. This study is observational in nature and does not impose a therapy protocol, diagnostic/therapeutic interventions or a visit schedule.
Patients with endogenous Cushing's Syndrome who are treated with osilodrostat alone or in combination with other therapies will be considered eligible for study enrolment. Each patient enrolled in the study will be followed up for 3 years from study entry. Patients who discontinue prior to the end of the 3-year period will be followed-up for 3 months after discontinuation of osilodrostat and will be included in the analysis.
The total number of patients enrolled in this study will be at least 100. Assuming a recruitment period of 3 years, the total study duration from First Patient First Visit (FPFV) to Last Patient Last Visit (LPLV) will be 6 years. The maximum duration for the individual patient is 3 years.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Osilodrostat Osilodrostat - tablets of 1mg, 5mg, 10mg - based on patients needs - up to 3 years |
Drug: Osilodrostat
oral administration of Osilodrostat tablets at different doses according to patient's need
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Incidence of osilodrostat-related adverse events and serious adverse events [3 years of treatment with osilodrostat]
Number of participants with Adverse Events and Serious Adverse Events
Secondary Outcome Measures
- Short and long-term efficacy of osilodrostat [at baseline before treatment start, after 1 month of treatment, then every 3 months in the first year and every 6 months thereafter through study completion up to three years]
Complete response rate: proportion of enrolled patients with mean Urinary Free Cortisol (mUFC) ≤ ULN
- Short and long-term efficacy of osilodrostat [at baseline before treatment start, after 1 month of treatment, then every 3 months in the first year and every 6 months thereafter through study completion up to three years]
Partial response rate: proportion of enrolled patients with ≥ 50% reduction from baseline in mean urinary free cortisol (mUFC), (but mUFC > ULN)
- Short and long-term efficacy of osilodrostat [at baseline before treatment start, after 1 month of treatment, then every 3 months in the first year and every 6 months thereafter through study completion up to three years]
Overall response rate: proportion of enrolled patients with mean urinary free cortisol (mUFC) ≤ ULN or at least 50% reduction from baseline
- Changes in pituitary tumour size [at baseline before treatment start, after 6 months of treatment, then every 12 months through study completion up to three years]
Actual and percentage change from baseline in pituitary tumour size
- Incidence of Adverse Events (Safety and Tolerability) [3 years of treatment with osilodrostat]
Incidence of adverse events and laboratory abnormalities using the National Cancer Institute-Common Toxicology Criteria (NCI-CTC) grading scale (version 5.0).
- Change of mean urinary free cortisol (mUFC) [at baseline before treatment start, after 1 month of treatment, then every 3 months through study completion up to three years]
Actual and percentage change from baseline in mean urinary free cortisol (mUFC)
- Change of Serum Cortisol [at baseline before treatment start, after 1 month of treatment, then every 3 months through study completion up to three years]
Actual and percentage change from baseline in Serum Cortisol
- Change of Late Salivary Cortisol [at baseline before treatment start, after 1 month of treatment, then every 3 months through study completion up to three years]
Actual and percentage change from baseline in Late Salivary Cortisol
- Change of adrenocorticotropic hormone (ACTH) [at baseline before treatment start, after 1 month of treatment, then every 3 months through study completion up to three years]
Actual and percentage change from baseline in adrenocorticotropic hormone (ACTH)
- Normalization of Serum Cortisol [at baseline before treatment start, after 1 month of treatment, then every 3 months through study completion up to three years]
Proportion of patients achieving normalisation of Serum Cortisol
- Normalization of Late Salivary Cortisol [at baseline before treatment start, after 1 month of treatment, then every 3 months through study completion up to three years]
Proportion of patients achieving normalisation of Late Salivary Cortisol
- Normalization of adrenocorticotropic hormone (ACTH) [at baseline before treatment start, after 1 month of treatment, then every 3 months through study completion up to three years]
Proportion of patients achieving normalisation of adrenocorticotropic hormone (ACTH)
- Change in Fasting Glucose [at baseline before treatment start, then every 3 months through study completion up to three years]
Actual and percentage change from baseline in fasting glucose
- Change in HbA1c [at baseline before treatment start, then every 3 months through study completion up to three years]
Actual and percentage change from baseline in HbA1c
- Change in Fasting Lipid Profile [at baseline before treatment start, then every 3 months through study completion up to three years]
Actual and percentage change from baseline in Fasting Lipid Profile
- Change in Serum Insulin [at baseline before treatment start, then every 3 months through study completion up to three years]
Actual and percentage change from baseline in Serum Insulin
- Change in Blood Pressure [at baseline before treatment start, after 1 month of treatment, then every 3 months through study completion up to three years]
Actual and percentage change from baseline in Blood Pressure
- Change in Body Weight [at baseline before treatment start, after 1 month of treatment, then every 3 months through study completion up to three years]
Actual and percentage change from baseline in Body Weight
- Change in Body Mass Index (BMI) [at baseline before treatment start, after 1 month of treatment, then every 3 months through study completion up to three years]
Actual and percentage change from baseline in Body Mass Index (BMI)
- Change in Waist Circumference [at baseline before treatment start, after 1 month of treatment, then every 3 months through study completion up to three years]
Actual and percentage change from baseline in Waist Circumference
- Change in Facial Rubor [at baseline before treatment start, after 3 months of treatment, after 6 months of treatment, then every 6 months through study completion up to three years]
Change from baseline in incidence and grade of severity at physical examination of the Cushing's syndrome clinical feature Facial Rubor
- Change in Hirsutism [at baseline before treatment start, after 3 months of treatment, after 6 months of treatment, then every 6 months through study completion up to three years]
Change from baseline in incidence and grade of severity at physical examination of the Cushing's syndrome clinical feature Hirsutism
- Change in Striae [at baseline before treatment start, after 3 months of treatment, after 6 months of treatment, then every 6 months through study completion up to three years]
Change from baseline in incidence and grade of severity at physical examination of the Cushing's syndrome clinical feature Striae
- Change in Supraclavicular fat pad [at baseline before treatment start, after 3 months of treatment, after 6 months of treatment, then every 6 months through study completion up to three years]
Change from baseline in incidence and grade of severity at physical examination of the Cushing's syndrome clinical feature Supraclavicular fat pad
- Change in Dorsal fat pad [at baseline before treatment start, after 3 months of treatment, after 6 months of treatment, then every 6 months through study completion up to three years]
Change from baseline in incidence and grade of severity at physical examination of the Cushing's syndrome clinical feature Dorsal fat pad
- Change in Proximal muscle wasting (atrophy) [at baseline before treatment start, after 3 months of treatment, after 6 months of treatment, then every 6 months through study completion up to three years]
Change from baseline in incidence and grade of severity at physical examination of the Cushing's syndrome clinical feature Proximal muscle wasting (atrophy)
- Change in Central (abdominal) obesity [at baseline before treatment start, after 3 months of treatment, after 6 months of treatment, then every 6 months through study completion up to three years]
Change from baseline in incidence and grade of severity at physical examination of the Cushing's syndrome clinical feature Central (abdominal) obesity
- Change in Ecchymoses (bruises) [at baseline before treatment start, after 3 months of treatment, after 6 months of treatment, then every 6 months through study completion up to three years]
Change from baseline in incidence and grade of severity at physical examination of the Cushing's syndrome clinical feature Ecchymoses (bruises)
- Changes in Patient-Reported Outcome (PRO) questionnaire Cushing Quality of Life (QoL) [at baseline before treatment start, after 3 months of treatment, after 6 months of treatment, then every 6 months through study completion up to three years]
Actual and percentage change from baseline in score of PRO questionnaire CushingQoL. The minimum and maximum values are 12 and 60 respectively, where higher score means a better outcome
- Changes in Patient-Reported Outcome (PRO) questionnaire Euro Quality of Life (EQ) - 5 Dimensions (5D) - 5 Levels (5L) [at baseline before treatment start, after 3 months of treatment, after 6 months of treatment, then every 6 months through study completion up to three years]
Actual and percentage change from baseline in score of PRO questionnaire EQ-5D-5L. The minimum and maximum values for the questions are 11111 and 55555 respectively, where higher score is a worst outcome. For the visual analogue scale minimum and maximum values are 0 and 100 respectively, where higher score means a better outcome
- Changes in Patient-Reported Outcome (PRO) questionnaire Beck Depression Inventory II (BDI-II) [at baseline before treatment start, after 3 months of treatment, after 6 months of treatment, then every 6 months through study completion up to three years]
Actual and percentage change from baseline in score of PRO questionnaire BDI-II. The minimum and maximum values are 1 and 63 respectively, where higher score means a worse outcome
- Changes in Patient-Reported Outcome (PRO) questionnaire Patient Global Impression of Change (PGIC) [after 3 months of treatment, after 6 months of treatment, then every 6 months through study completion up to three years]
Actual and percentage change in score of PRO questionnaire PGIC. The minimum and maximum values of the question are 1 and 7 respectively, where higher score means a better outcome. For the visual analogue scale minimum and maximum values are 0 and 10 respectively, where higher score means a worse outcome
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Written informed consent obtained prior to registration of any patient data
-
Male or female patients aged 18 years or older with endogenous CS treated with osilodrostat. Treatment with osilodrostat can either be initiated at the first visit of the study or can have been initiated before screening.
Exclusion Criteria:
-
Patients with exogenous CS
-
Patients with Pseudo CS
-
Patients participating in an interventional clinical trial with an investigational drug.
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- RECORDATI GROUP
Investigators
- Study Chair: Alberto M Pedroncelli, MD, Recordati AG - Medical Director
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- LCI699-RECAG-PASS-0572